中国生物制药：集团自主研发的1类创新药罗伐昔替尼上市获得药监局上市批准

财经网03-02

近日，中国生物制药发布公告称，集团自主研发的国家1类创新药罗伐昔替尼片（商品名：安煦®）已获得中国国家药品监督管理局(NMPA)的上市批准，适用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)成年患者的一线治疗。在一项多中心、随机、双盲、双模拟、阳性药物平行对照的II期临床研究中，罗伐昔替尼对比羟基尿在治疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616332509?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-02 17:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2616332509","market":"us","top_or_hot":-1,"title":"中国生物制药：集团自主研发的1类创新药罗伐昔替尼上市获得药监局上市批准","media":"财经网","content":"<div>\n<p>近日，中国生物制药发布公告称，集团自主研发的国家1类创新药罗伐昔替尼片（商品名：安煦®）已获得中国国家药品监督管理局(NMPA)的上市批准，适用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)成年患者的一线治疗。在一项多中心、随机、双盲、双模拟、阳性药物平行对照的II期临床研究中，罗伐昔替尼对比羟基尿在治疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302173018a731073c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药：集团自主研发的1类创新药罗伐昔替尼上市获得药监局上市批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药：集团自主研发的1类创新药罗伐昔替尼上市获得药监局上市批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 17:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302173018a731073c&s=b><strong>财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，中国生物制药发布公告称，集团自主研发的国家1类创新药罗伐昔替尼片（商品名：安煦®）已获得中国国家药品监督管理局(NMPA)的上市批准，适用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)成年患者的一线治疗。在一项多中心、随机、双盲、双模拟、阳性药物平行对照的II期临床研究中，罗伐昔替尼对比羟基尿在治疗...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302173018a731073c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMF","symbol_name":"太平洋投资管理市政收益基金","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302173018a731073c&s=b","article_id":"2616332509","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302173018a731073c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616332509","pubTimestamp":1772443607,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，中国生物制药发布公告称，集团自主研发的国家1类创新药罗伐昔替尼片已获得中国国家药品监督管理局的上市批准，适用于中危-2或高危的原发性骨髓纤维化、真性红细胞增多症后骨髓纤维化或原发性血小板增多症后骨髓纤维化成年患者的一线治疗。在一项多中心、随机、双盲、双模拟、阳性药物平行对照的II期临床研究中，罗伐昔替尼对比羟基尿在治疗中危-2、高危骨髓纤维化患者中展示出优异的疗效和良好的安全性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PMF":"太平洋投资管理市政收益基金","SBHMY":"中国生物制药ADR","BK4007":"制药"},"translate_title":"China Biopharmaceuticals: The Group's independently developed Class 1 innovative drug rovacitinib was approved by the Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMF":1,"SBHMY":0.9},"content_text":"近日，中国生物制药发布公告称，集团自主研发的国家1类创新药罗伐昔替尼片（商品名：安煦®）已获得中国国家药品监督管理局(NMPA)的上市批准，适用于中危-2或高危的原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)或原发性血小板增多症后骨髓纤维化(PET-MF)成年患者的一线治疗。在一项多中心、随机、双盲、双模拟、阳性药物平行对照的II期临床研究中，罗伐昔替尼对比羟基尿在治疗中危-2、高危骨髓纤维化患者中展示出优异的疗效和良好的安全性。研究结果显示，罗伐昔替尼组在第24周脾脏体积较基线缩小≥35%(SVR35)的受试者比例为58.33%，任意时间点达到SVR35的比例为63.89%，SVR35平均持续时间长达8.31个月，最佳总症状评分改善≥50%(TSS50)率高达77.78%。该药物的总体耐受性良好，≥3级不良反应发生率约40%，贫血发生率约40%，治疗终止率仅为6.7%。（中国生物制药公告）(编辑：杨燕 林辰)关键字： 医疗","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616332509","isCrawlerRequest":true}